Falla will remain with the developer of bioactive peptides on a consulting basis during the transition period, to manage the company’s patent portfolio: one which he has helped to build over the last ten years.
“Our patent portfolio has grown to cover more than 100,000 bioactive peptides, one of the most extensive libraries in the industry. A number of these molecules are now contributing to our growing revenue base, and Helix BioMedix is intensifying its focus on the near-term commercialization of its extensive peptide and small molecule library,” stated R. Stephen Beatty, company CEO.
“We are pleased that Tim will continue to assist the company with matters related to existing patents and patent applications. Dr Lijuan Zhang, who has worked alongside Tim in creating the current patent portfolio, will continue to lead our ongoing invention and discovery programs targeting the development of novel molecules,” he added.